0.01% Less Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB) Short Interest

June 29, 2018 - By Theresa McIntyre

It was showed a decrease on Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB)’s short interest with 0.01%. FINRA issued in June ZLAB’s total 1.85M short interest. The 1.86M previous shares are down with 0.01%. Previous ZLAB’s position will need 31 days to recover. It has 60,300 average volume. Zai Lab Limited – American Depositary Shares’s short interest float is 65.15%.

The stock increased 1.09% or $0.2486 during the last trading session, reaching $23.0386.Zai Lab Limited has volume of 11,052 shares. Since June 29, 2017 ZLAB has 0.00% and is . ZLAB underperformed by 12.57% the S&P500.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China.The firm is valued at $1.17 billion. The Company’s drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.Currently it has negative earnings.

More recent Zai Lab Limited (NASDAQ:ZLAB) news were posted by Nasdaq.com, Globenewswire.com and Benzinga.com. The first one has “Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line …” as a title and was posted on June 29, 2018. The next is “Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer” on June 05, 2018. And last was posted on June 03, 2018, called “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.